Montag A & Associates Inc. Cuts Position in Edwards Lifesciences Co. (NYSE:EW)

Montag A & Associates Inc. reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,067 shares of the medical research company’s stock after selling 1,886 shares during the period. Montag A & Associates Inc.’s holdings in Edwards Lifesciences were worth $3,706,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Alpha Financial Partners LLC purchased a new position in Edwards Lifesciences in the third quarter valued at about $693,000. Trust Co. of Vermont increased its stake in Edwards Lifesciences by 36.1% in the 3rd quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 801 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in Edwards Lifesciences by 10.6% during the third quarter. V Square Quantitative Management LLC now owns 15,026 shares of the medical research company’s stock worth $992,000 after purchasing an additional 1,437 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new stake in Edwards Lifesciences during the third quarter worth $273,000. Finally, Net Worth Advisory Group acquired a new stake in Edwards Lifesciences in the third quarter valued at $437,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,555,402. The trade was a 12.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock valued at $2,002,829 over the last three months. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE EW opened at $76.23 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market capitalization of $44.96 billion, a P/E ratio of 11.00, a P/E/G ratio of 3.64 and a beta of 1.10. The business’s 50-day simple moving average is $72.67 and its 200-day simple moving average is $69.50.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Equities analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of several recent research reports. Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday. Finally, Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.